Stock-Based Compensation (Tables)

3 Months Ended

Mar. 31, 2022

Share-based Payment Arrangement [Abstract]

Fair Value of Options Estimated on Date of Grant Using Black-Scholes Option Pricing Model

Under the 2019 Plan, the fair value of the Baudax Bio options was estimated on the date of grant using a Black-Scholes option pricing model with the following weighted average assumptions:

	March 31,
	2021
Expected option life	5.5 years
Expected volatility	75.68%
Risk-free interest rate	0.68%
Expected dividend yield		—

Summary of Stock Option Activity

The following table summarizes Baudax Bio stock option activity during the three months ended March 31, 2022:

	Number of shares			Weighted average exercise price		Weighted average remaining contractual life
Balance, December 31, 2021		125,418		$	76.05	8.6 years
Expired/forfeited/cancelled		(15,338	)	$	46.57
Balance, March 31, 2022		110,080		$	80.16	7.5 years
Vested		56,462		$	87.67	6.0 years
Vested and expected to vest		110,080		$	80.16	7.5 years

Summary of RSUs Activity

The following table summarizes Baudax Bio RSUs activity during the three months ended March 31, 2022:

	Number of shares			Weighted average grant date fair value
Balance, December 31, 2021		41,069		$	63.79
Vested and settled		(1,484	)		48.54
Expired/forfeited/cancelled		(4,076	)		44.86
Balance, March 31, 2022		35,509		$	66.60
Expected to vest		20,383